Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab

R. Channa, R. Sophie, A. A. Khwaja, D. V. Do, Gulnar Hafiz, Q. D. Nguyen, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P

Original languageEnglish (US)
Pages (from-to)269-278
Number of pages10
JournalEye (London, England)
Volume28
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Macular Edema
Visual Acuity
Fluorescein
Edema
Angiography
Tomography
Ranibizumab

Keywords

  • Anti-VEGF
  • Diabetic macular edema
  • Macular edema
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. / Channa, R.; Sophie, R.; Khwaja, A. A.; Do, D. V.; Hafiz, Gulnar; Nguyen, Q. D.; Campochiaro, Peter A.

In: Eye (London, England), Vol. 28, No. 3, 2014, p. 269-278.

Research output: Contribution to journalArticle

Channa, R. ; Sophie, R. ; Khwaja, A. A. ; Do, D. V. ; Hafiz, Gulnar ; Nguyen, Q. D. ; Campochiaro, Peter A. / Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. In: Eye (London, England). 2014 ; Vol. 28, No. 3. pp. 269-278.
@article{57b920c421914ec4b08be8740519a0ba,
title = "Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab",
abstract = "PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27{\%}) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P",
keywords = "Anti-VEGF, Diabetic macular edema, Macular edema, Ranibizumab",
author = "R. Channa and R. Sophie and Khwaja, {A. A.} and Do, {D. V.} and Gulnar Hafiz and Nguyen, {Q. D.} and Campochiaro, {Peter A}",
year = "2014",
doi = "10.1038/eye.2013.245",
language = "English (US)",
volume = "28",
pages = "269--278",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab

AU - Channa, R.

AU - Sophie, R.

AU - Khwaja, A. A.

AU - Do, D. V.

AU - Hafiz, Gulnar

AU - Nguyen, Q. D.

AU - Campochiaro, Peter A

PY - 2014

Y1 - 2014

N2 - PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P

AB - PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P

KW - Anti-VEGF

KW - Diabetic macular edema

KW - Macular edema

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84896356110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896356110&partnerID=8YFLogxK

U2 - 10.1038/eye.2013.245

DO - 10.1038/eye.2013.245

M3 - Article

C2 - 24263379

AN - SCOPUS:84896356110

VL - 28

SP - 269

EP - 278

JO - Eye

JF - Eye

SN - 0950-222X

IS - 3

ER -